Ezra provides AI-enhanced full-body MRI screening that monitors for possible cancer and 500+ conditions across up to 13 organs, using proprietary AIs for imaging, analysis, and reporting. The company holds FDA clearance for Ezra Flash AI, which enabled the launch of a 30-minute full-body MRI scan. Ezra says its AI innovations have reduced the price of its full-body MRI by 40%, making scans more affordable and increasing throughput for imaging centers. The company doubled its revenue in 2023 and currently operates 18 locations across New York, New Jersey, Los Angeles, Irvine, San Francisco, Miami, and Las Vegas. Ezra plans to expand to 20 cities and 50 locations across North America in 2024 and will continue building AIs for imaging centers and clinicians. The company is also on track to introduce a 15-minute full-body MRI priced at around $500 within two to three years. Ezra is a New York–based company that offers MRI-based early cancer screening supported by artificial intelligence and board-certified radiologist reads. The company launched an MRI-based prostate cancer screening program in January 2019 and introduced a full-body MRI scan in May 2019. Ezra partners with outpatient imaging facilities and has screening programs live in New York City, San Francisco, and Los Angeles through a partnership with RadNet, Inc. It maintains R&D operations in Toronto. The company intends to use new funding to expand its medical imaging AIs to make MRI-based cancer screening more accessible and to roll out Ezra COVID 360, a low-dose CT lung scan paired with an antibody blood test. Ezra COVID 360 will be available for $390 in New York City starting June 1st, with plans to expand across California and to provide 50 free plans to medical providers and first responders. Ezra offers an MRI-based prostate cancer screening subscription that purchases MRI time in bulk and provides one MRI per year, access to medical staff, educational guides, and follow-up support. The service launched v1 in New York City and charges $999 per year; Ezra reports a roughly 50% gross margin on these subscriptions. Human radiologists currently analyze scans while the company is developing an AI that agreed with experts about 90% of the time on a test dataset and is pursuing FDA approval next year to assist radiologists and reduce labor costs. Ezra has partnered with RadNet to buy MRI slots starting at Lenox Hill in Manhattan and plans to expand to additional RadNet locations beyond NYC next year. The company aims to scale the model toward broader or full-body MRI screening to detect more cancers earlier. Key challenges noted include persuading insurers that upfront MRI screening is more cost‑efficient than the biopsy status quo and finding a balance between margins and affordability.

Total raised

$43M

Funding rounds

3

Latest round

Equity

Latest activity

Feb 2024